DelveInsight’s report titled “Gastrointestinal Stromal Tumor (GIST) Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes Gastrointestinal Stromal Tumor (GIST). The report provides a comprehensive analysis of historical and projected epidemiological data, covering Total Incident Cases of Gastrointestinal Stromal Tumor (GIST), Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), and Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST).
Discover Key Insights into the Gastrointestinal Stromal Tumor Market with DelveInsight’s In-Depth Report @ Gastrointestinal Stromal Tumor Market Size
Key Takeaways from Gastrointestinal Stromal Tumor Market Report
- In the assessment done by DelveInsight, the estimated total incident cases of GIST in the 7MM were nearly 16 thousand in 2023.
- The highest incident cases of GIST were accounted by the US in 2023 (approximately 7k cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 43% of the total cases in the 7MM.
- In 2023, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with nearly 6 thousand cases in the 7MM, followed by age group 51-65 years with around 5 thousand cases. While the least number of cases were seen in the age group 0-17 years.
- Among the European countries, Germany had the highest incident population of GIST with nearly 2 thousand cases, followed by Italy, which had incident population of over 1k in 2023. On the other hand, Spain had the lowest incident population.
- Japan had more than 2,500 incident cases for GIST in 2023, accounting for approximately 16% of total incident cases in the 7MM.
- In 2023, our estimations indicate that within the 7MM, a higher percentage of males (52%) were affected by Gastrointestinal Stromal Tumor (GIST) compared to females (48%). The reason for this gender difference could be attributed to various factors, including potential differences in genetic susceptibility, hormonal influences, occupational exposures, lifestyle habits, and healthcare-seeking behaviors.
- The leading Gastrointestinal Stromal Tumor Companies such as Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
- Promising Gastrointestinal Stromal Tumor Therapies such as TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
Stay ahead in the Gastrointestinal Stromal Tumor Therapeutics Market with DelveInsight’s Strategic Report @ Gastrointestinal Stromal Tumor Market Outlook
Gastrointestinal Stromal Tumor Epidemiology Segmentation in the 7MM
- Total Gastrointestinal Stromal Tumor Prevalence
- Prevalent Cases of Gastrointestinal Stromal Tumor by severity
- Gastrointestinal Stromal Tumor Gender-specific Prevalence
- Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor
Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Prevalence
Gastrointestinal Stromal Tumor Marketed Therapies
- Ayvakit (Avapritinib): Blueprint Medicines Corporation
Ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations and Advanced Systemic Mastocytosis (AdvSM). The FDA granted full approval to Ayvakit based on efficacy results from the Phase I NAVIGATOR clinical trial, as well as combined safety results from multiple clinical trials for avapritinib.
- STIVARGA (Regorafenib): Bayer
Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or metastatic GIST who have previously received imatinib mesylate and sunitinib malate. In September 2021, Bayer presented study results indicating close proximity to the prespecified activity threshold, possibly influenced by a low recruitment rate. The notable frequency of undetected mutant GIST by Sanger sequencing underscores the importance of next-generation sequencing (NGS) in presumed KIT/PDGFR wild-type GIST.
Gastrointestinal Stromal Tumor Emerging Therapies
- Crenolanib: Arog Pharmaceuticals
Crenolanib, an investigational small molecule drug, is currently undergoing Phase III clinical trials to assess its safety and efficacy in treating acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST). Acting as a potent inhibitor of both wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFRα/β (Platelet-derived Growth Factor Receptor), Crenolanib holds promise as a potential additional treatment option for patients with advanced or metastatic GIST harboring a D842V mutation in the PDGFRA gene, offering hope for improved outcomes in this specific subgroup.
- Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.
Bezuclastinib (CGT9486) is a highly selective Type I inhibitor of KIT receptor tyrosine kinase, specifically targeting oncogenic KIT with mutations in the activation loop encoded by exons 17 and 18, including the pivotal KIT D816V mutation found in the majority of patients with systemic mastocytosis. The combination of bezuclastinib with sunitinib, a Type-II inhibitor effective against KIT ATP-binding pocket mutations, demonstrated prolonged progression-free survival in extensively treated patients with gastrointestinal stromal tumor. Cogent Biosciences, Inc. holds worldwide rights to bezuclastinib, encompassing all facets of development, manufacturing, and commercialization activities related to this promising molecule.
Get In-Depth Knowledge on Gastrointestinal Stromal Tumor Market Trends and Forecasts with DelveInsight @ Gastrointestinal Stromal Tumor Treatment Market
Gastrointestinal Stromal Tumor Market Outlook
Knowledge about the underlying genetic alterations revealed possible targeted treatment with TKIs such as imatinib and sunitinib. Continuous research efforts helped to further elucidate molecular insights of this disease and allowed the development of new treatment options based on the underlying molecular signature. Currently, there are seven therapies approved for GIST that includes five TKIs, and two NTRK inhibitors such as GLEEVEC (Imatinib Mesylate), STIVARGA (Regorafenib), SUTENT (sunitinib malate), AYVAKIT (avapritinib), QINLOCK (Ripretinib), ROZLYTREK (Entrectinib), and VITRAKVI (Larotrectinib), approved in different lines. Along with these, there are certain therapies being used as off-label therapies in patients resistant to approved therapies.
Scope of the Gastrointestinal Stromal Tumor Market Report
- Study Period: 2020–2034
- Coverage: 7MM
- Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
- Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
- Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
- Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Gastrointestinal Stromal Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastrointestinal Stromal Tumor Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Gastrointestinal Stromal Tumor Market Report @ Gastrointestinal Stromal Tumor Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Gastrointestinal Stromal Tumor Market Overview at a Glance
4 Gastrointestinal Stromal Tumor Market and Epidemiology Methodology
5 Executive Summary of Gastrointestinal Stromal Tumors
6 Key Events
7 Gastrointestinal Stromal Tumor: Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Gastrointestinal Stromal Tumor: Seven Major Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Reimbursement and Market Access
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services